Latest News by Industry
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $52.4 million in its second quarter.
On a per-share basis, the San Francisco-based company said it had a loss of 25 cents.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.
The biopharmaceutical company posted revenue of $23.5 million in the period, surpassing Street forecasts. Five analysts surveyed by Zacks expected $17.2 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR